Balance test results. by Le Zhu (1771669)

Subjects:

Variables. by Le Zhu (1771669)

Subjects:

Results of the parallel trend test. by Le Zhu (1771669)

Subjects:

Results of the exclusion of other policies. by Le Zhu (1771669)

Subjects:

Results of robustness tests. by Le Zhu (1771669)

Subjects:

Descriptive statistical of variables. by Le Zhu (1771669)

Subjects:

The results of Bootstrap Method and Sobel Test. by Le Zhu (1771669)

Subjects:

Placebo test. by Le Zhu (1771669)

Subjects:

Baseline regression results. by Le Zhu (1771669)

Subjects:

 'Plan-B':  Impact of changes in the global funding landscape for Hepatitis B clinical and research programmes by marion delphin (13249479)

“…One-third of respondents reported already experiencing significant impact from funding changes, while over two-thirds expressed high concerns about future effects. …”

Mean Values and Standard Deviations (Mean [±SD]) of Clinical Parameters: periodontal probing depth (PPD), clinical attachment level (CAL), bleeding on probing (BOP), and plaque ind... by Iva Milinkovic (22331710)

Subjects:

Demographic and clinical data at baseline. by Karel Joineau (21799908)

Subjects:

Multiple linear regression analysis of the RAAS and glucose metabolism indicators before and after treatment in DKD and non-DKD patients. by Ningning Wang (560944)

Clinical characteristics. by Huimin Xian (20390006)

“…</p><p>Conclusions</p><p>In patients with MVD-STEMI, the incidence of MACEs was lower in FCR than in FIR, and the decrease was particularly significant in the DM cohort. …”

Clinical characteristics of reports with finasteride as the primary suspected drug from the FAERS database. by Xiaoling Zhong (181270)

Subjects:

Political events and impacts in different periods. by Jie Li (15030)

Clinical diagnosis and abnormal signals of AEFIs(/10,000). by Chao Zhang (51048)

Univariate and multivariate logistic regression analyses of the impact of Safe-Speed-5030 on the study population. by Hun Gi Lee (21526538)

Image 3_Endolysin significantly improves symptoms with atopic dermatitis: bridging the gap from research to clinical practice.jpeg by Ling Kui (6108440)

“…Compared to baseline, EASI, SCORAD, IGA, VAS, and DLQI scores demonstrated significant decreases at both Day 7 and Day 14 (all P < 0.05). …”

Image 4_Endolysin significantly improves symptoms with atopic dermatitis: bridging the gap from research to clinical practice.jpeg by Ling Kui (6108440)

“…Compared to baseline, EASI, SCORAD, IGA, VAS, and DLQI scores demonstrated significant decreases at both Day 7 and Day 14 (all P < 0.05). …”